These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 38013636)

  • 1. The impact of margin reduction on radiation dose distribution of ultra-hypofractionated prostate radiotherapy utilizing a 1.5-T MR-Linac.
    Onal C; Efe E; Bozca R; Yavas C; Yavas G; Arslan G
    J Appl Clin Med Phys; 2024 Jan; 25(1):e14179. PubMed ID: 38013636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetric comparison of MR-linac-based IMRT and conventional VMAT treatment plans for prostate cancer.
    Da Silva Mendes V; Nierer L; Li M; Corradini S; Reiner M; Kamp F; Niyazi M; Kurz C; Landry G; Belka C
    Radiat Oncol; 2021 Jul; 16(1):133. PubMed ID: 34289868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetric evaluation of ultrafractionated dose escalation with simultaneous integrated boost to intraprostatic lesion using 1.5-Tesla MR-Linac in localized prostate cancer.
    Onal C; Arslan G; Yavas C; Efe E; Yavas G
    Rep Pract Oncol Radiother; 2024; 29(1):10-20. PubMed ID: 39165591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetric effects of adaptive prostate cancer radiotherapy in an MR-linac workflow.
    Mannerberg A; Persson E; Jonsson J; Gustafsson CJ; Gunnlaugsson A; Olsson LE; Ceberg S
    Radiat Oncol; 2020 Jul; 15(1):168. PubMed ID: 32650811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target miss using PTV-based IMRT compared to robust optimization via coverage probability concept in prostate cancer.
    Outaggarts Z; Wegener D; Berger B; Zips D; Paulsen F; Bleif M; Thorwarth D; Alber M; Dohm O; Müller AC
    Acta Oncol; 2020 Aug; 59(8):911-917. PubMed ID: 32436467
    [No Abstract]   [Full Text] [Related]  

  • 6. Retrospective study comparing MR-guided radiation therapy (MRgRT) setup strategies for prostate treatment: repositioning vs. replanning.
    Kim JI; Park JM; Choi CH; An HJ; Kim YJ; Kim JH
    Radiat Oncol; 2019 Aug; 14(1):139. PubMed ID: 31387593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a simplified optimizer for MR-guided adaptive RT in case of pancreatic cancer.
    Cusumano D; Boldrini L; Menna S; Teodoli S; Placidi E; Chiloiro G; Placidi L; Greco F; Stimato G; Cellini F; Valentini V; Azario L; De Spirito M
    J Appl Clin Med Phys; 2019 Sep; 20(9):20-30. PubMed ID: 31444952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Intensity Modulated Radiotherapy Treatment Plans Between 1.5T MR-Linac and Conventional Linac.
    Ding S; Li Y; Liu H; Li R; Wang B; Zhang J; Chen Y; Huang X
    Technol Cancer Res Treat; 2021; 20():1533033820985871. PubMed ID: 33472549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Volumetric-modulated arc therapy for the treatment of a large planning target volume in thoracic esophageal cancer.
    Abbas AS; Moseley D; Kassam Z; Kim SM; Cho C
    J Appl Clin Med Phys; 2013 May; 14(3):4269. PubMed ID: 23652258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of Isotoxic Dose Escalation and Plan Quality with TDABC Analysis on a 0.35 T MR-Linac (MRL) System in Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided Radiation Therapy (MRgRT) for Primary Pancreatic Cancer.
    Hawranko R; Sohn JJ; Neiderer K; Bump E; Harris T; Fields EC; Weiss E; Song WY
    J Clin Med; 2022 May; 11(9):. PubMed ID: 35566712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTV-based IMPT optimization incorporating planning risk volumes vs robust optimization.
    Liu W; Frank SJ; Li X; Li Y; Zhu RX; Mohan R
    Med Phys; 2013 Feb; 40(2):021709. PubMed ID: 23387732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Image-guided IMRT for localized prostate cancer with daily repositioning: inferring the difference between planned dose and delivered dose distribution.
    Arnaud A; Maingon P; Gauthier M; Naudy S; Dumas JL; Martin E; Peignaux-Casasnovas K; Truc G; Bonnetain F; Crehange G
    Phys Med; 2014 Sep; 30(6):669-75. PubMed ID: 24792687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI-based IMRT planning for MR-linac: comparison between CT- and MRI-based plans for pancreatic and prostate cancers.
    Prior P; Chen X; Botros M; Paulson ES; Lawton C; Erickson B; Li XA
    Phys Med Biol; 2016 May; 61(10):3819-42. PubMed ID: 27089554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetric study of uniform scanning proton therapy planning for prostate cancer patients with a metal hip prosthesis, and comparison with volumetric-modulated arc therapy.
    Rana S; Cheng C; Zheng Y; Hsi W; Zeidan O; Schreuder N; Vargas C; Larson G
    J Appl Clin Med Phys; 2014 May; 15(3):4611. PubMed ID: 24892333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of dose calculation accuracy during optimization on lung IMRT plan quality.
    Li Y; Rodrigues A; Li T; Yuan L; Yin FF; Wu QJ
    J Appl Clin Med Phys; 2015 Jan; 16(1):5137. PubMed ID: 25679172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity-modulated radiation therapy for pancreatic and prostate cancer using pulsed low-dose rate delivery techniques.
    Li J; Lang J; Wang P; Kang S; Lin MH; Chen X; Chen F; Guo M; Chen L; Ma CM
    Med Dosim; 2014; 39(4):330-6. PubMed ID: 25087084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dosimetric comparison of intensity-modulated radiotherapy versus rapid arc in gynecological malignancies: Dose beyond planning target volume, precisely 5Gy volume.
    Sidhu MS; Singh K; Sood S; Aggarwal R
    J Cancer Res Ther; 2023; 19(5):1267-1271. PubMed ID: 37787294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Passive proton therapy vs. IMRT planning study with focal boost for prostate cancer.
    Yeo I; Nookala P; Gordon I; Schulte R; Barnes S; Ghebremedhin A; Wang N; Yang G; Ling T; Bush D; Slater J; Patyal B
    Radiat Oncol; 2015 Oct; 10():213. PubMed ID: 26499318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dosimetric comparison of RapidArc and IMRT with hypofractionated simultaneous integrated boost to the prostate for treatment of prostate cancer.
    Ishii K; Ogino R; Okada W; Nakahara R; Kawamorita R; Nakajima T
    Br J Radiol; 2013 Oct; 86(1030):20130199. PubMed ID: 23995872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Volumetric-modulated arc therapy vs. c-IMRT in esophageal cancer: a treatment planning comparison.
    Yin L; Wu H; Gong J; Geng JH; Jiang F; Shi AH; Yu R; Li YH; Han SK; Xu B; Zhu GY
    World J Gastroenterol; 2012 Oct; 18(37):5266-75. PubMed ID: 23066322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.